Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 18/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.80 |
| ▸ | CLK2 | P49760 | 1/20 | 0.72 |
| ▸ | BLK | P51451 | 1/20 | 0.72 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.72 |
| ▸ | STK3 | Q13188 | 1/20 | 0.72 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.72 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.72 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.72 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17040581 | 0.93 | ROCK2 (0.87) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL10218675 | 0.90 | ROCK2 (0.82) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL15638917 | 0.89 | ROCK2 (0.85) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL17038102 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL17041187 | 0.86 | ROCK2 (0.75) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL17040955 | 0.85 | ROCK2 (0.78) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL17038108 | 0.85 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL878258 | 0.84 | ROCK2 (0.91) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Trifluoroacetic Acid SCHEMBL29575691 | 0.84 | ROCK2 (0.72) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL17040958 | 0.84 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4116293-A2 | RHO KINASE INHIBITORS | Kadmon Corporation, LLC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| EP-2903618-B1 | RHO KINASE INHIBITORS | KADMON CORP LLC (US) | 2022-06-01 | — | — | EP | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210147391-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION LLC | 2021-05-20 | — | — | US | disclosed |
| US-10696660-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190308953-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION LLC | 2019-10-10 | — | — | US | disclosed |
| US-10183931-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-9815820-B2 | Rho kinase inhibitors | KADMON CORPORATION, LLC (US) | 2017-11-14 | — | — | US | disclosed |
| US-20170112832-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC | 2017-04-27 | — | — | US | disclosed |
| US-20150252025-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2015-09-10 | — | — | US | disclosed |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | KADMON CORPORATION, LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696660-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 584/4885 |
| US-20170112832-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 2335/4885 |
| US-10183931-B2 | Rho kinase inhibitors | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 584/4885 |
| US-20150238601-A1 | TREATMENT OF OCULAR DISORDERS | ROCK2, KDR, FLT1 | ROCK2 1/4885ROCK1 5/4885CLK2 1747/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | ROCK2 1/4885ROCK1 2/4885CLK2 1806/4885 |
| US-20190308953-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 584/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 2335/4885 |
| US-20210147391-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 584/4885 |
| US-20150252025-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.